Can Covalon Technologies convert IV contamination education into adoption of VALGuard and CovaClear?
Covalon Technologies is gaining momentum in vascular access and wound care. Read why its latest milestones could shape medtech growth next.
Imbed Biosciences wins CMS HCPCS code for Microlyte PainGuard, but will billing clarity translate into wound care adoption?
Imbed Biosciences secured CMS HCPCS code A2040 for Microlyte PainGuard. Read what it changes for wound care adoption, billing, and reimbursement.
Why Vyome’s VT-1953 data could reshape supportive oncology care in advanced cancer wounds
Vyome’s VT-1953 heads to AACR 2026 with Phase 2 data in malignant fungating wounds. Read what this could change for supportive oncology.
BioStem acquires Neox and Clarix as BioTissue refocuses on eye care therapies
BioTissue exits surgical wound care to refocus on eye care innovation, selling Neox and Clarix lines to BioStem. Find out what this deal changes in MedTech.
BioTissue divests surgical and wound care business to BioStem, sharpening focus on ocular regeneration
BioTissue Holdings, Inc. has completed the divestiture of its non-ocular surgical and wound care business to BioStem Technologies, Inc. in a transaction valued at approximately $15 million upfront, with potential earnouts tied to regulatory and commercial milestones. The deal transfers ownership of the Neox and Clarix product lines, along with a seasoned commercial team and […]